PLX
Protalix BioTherapeutics, Inc.
Next earnings Aug 12, 2026 · consensus $-0.01 EPS, $13.1M rev
Last earnings +1.0% on 2026-05-13
$2.30
▲ +3.60%$2.30▲ +64.29%
over 1Y
L $1.35EODHDH $3.15
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.6%
1W+6.5%
1M+8.5%
3M+7.5%
YTD+32.2%
1Y+64.3%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 5 analysts
Buy
Conservative balance sheet (liabilities/equity 0.71x); but revenue declined -1.2% YoY.
Protalix BioTherapeutics, Inc. shows $52.7M in FY2025 revenue (-1.2% YoY), a -12.5% net margin, and -13.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $38.4M | $47.6M | $65.5M | $53.4M | $52.7M |
| Gross profit | — | — | — | — | — |
| Operating income | -$20.5M | -$13.0M | $10.5M | $3.92M | -$5.50M |
| Net income | -$27.6M | -$14.9M | $8.31M | $2.93M | -$6.60M |
| Diluted EPS | -$0.62 | -$0.31 | $0.09 | $0.04 | -$0.08 |
| Net margin | -71.9% | -31.3% | 12.7% | 5.5% | -12.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$172M
EV / EBITDA—
EV / Sales3.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-3.6%
FCF yield-7.4%
Quality & risk
ROIC (est.)-8.8%
Free cash flow-$13.6M
Total debt$912K
Net cash$13.8M
Altman Z-Score-2.28 distress
Piotroski F-Score3/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+3.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-252026-06-25open ↗8-KPeriod ending 2026-05-212026-05-21open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-132026-05-13open ↗ARSPeriod ending 2025-12-312026-04-30open ↗DEF 14APeriod ending 2026-06-252026-04-30open ↗3/APeriod ending 2025-08-242026-04-27open ↗SCHEDULE 13G/AFiling2026-03-30open ↗10-KPeriod ending 2025-12-312026-03-18open ↗8-KPeriod ending 2026-03-182026-03-18open ↗8-KPeriod ending 2026-03-092026-03-09open ↗SCHEDULE 13GFiling2026-03-04open ↗
Frequently asked
- Is Protalix BioTherapeutics, Inc. (PLX) a buy?
- PLX currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.71x); but revenue declined -1.2% YoY.
- What is Protalix BioTherapeutics, Inc.'s quality score?
- PLX scores 43.58823529411764/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001006281, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 6:56:08 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.